SANOFI INDIA LTD (SANOFI): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1YAll

₹3,329.3 latest close · −0.6% over the last 90 sessions

₹3,329.3 month-end · −22.4% over 12 months

₹3,329.3 month-end · −53.3% since Mar '24

52-week range ₹2698.30 to ₹4687.90 · 1-year volatility 22.6%

Was the rally earned?

-22%share price, 1 yearMultiple-driven

Mostly the multiple.

Most of the fall came from investors paying a lower multiple (P/E 23.9x to 18.5x); per-share earnings added 0 points.
The share count barely moved.

Net profit growth0 ptsNet profit was little changed.

P/E change-22 ptsThe P/E fell from 23.9x to 18.5x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-69.3%not yet recovered

1-year volatility22.6%annualised

Beta vs sector index0.543-year daily, correlation 0.28

Volume spikes5last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-69.3% (2024-06 peak to 2026-10 low, not yet recovered)

-42.4% (2021-08 peak to 2023-02 low, recovered 2024-02)

-20.1% (2020-03 peak to 2020-03 low, recovered 2020-04)

Most recent volume spikes

2026-11-04: 5.1x the 50-day median, price +2.0% that day

2026-10-30: 13.6x the 50-day median, price +0.5% that day

2026-10-29: 6.4x the 50-day median, price +6.6% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

18.5xP/E todayWithin its usual range

Against its own history21st percentile

CheapestMedian 26.6xDearest

Usual range 17.4x to 31.6x since 2024-03.

Against Health Technology18.5x vs 37.0x

This company

18.5x

Sector median

37.0x

50% below the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE97thflat vs a year ago
Op. margin69thflat vs a year ago
Revenue growth18th▼ 16 pts vs a year ago
EPS growth37th▲ 15 pts vs a year ago
Debt/equity ↓84thflat vs a year ago
Cash cycle ↓79th▲ 5 pts vs a year ago
P/E ↓80th▲ 12 pts vs a year ago
12M momentum13th▼ 15 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~10%annual earnings growth implied by the price

At a P/E of 18.5x, the price would imply about 10.1%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Earnings figures have not updated recently, so the company is left out of the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹3329.30
P/E: 18.5x
ROCE: 49.0%
Market Cap: ₹7668 cr
Revenue (TTM): ₹2014 cr
P/S: 3.8x
P/B: 8.9x
ROE: 48.1%
Operating Margin: 23.0%
Debt / Equity: 0.0x
Promoter Holding: 60.4%
12M Momentum: -22.4%

52-week range

₹2698.30₹4687.90

32% of the way from its 52-week low to its high

Price risk

1Y volatility

22.6%

Beta vs sector

1-year daily

0.41

Balance sheet & cash

Debt service

no meaningful debt

Share count, 1Y

unchanged

Are profits backed by cash?

3 of 4checks within range1 near a threshold

Other income reliance15%Within range

Other income as a share of pre-tax profit (trailing twelve months): 14.7%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate25%Within range

Median quarterly effective tax rate over about 2.5 years: 25.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow—Not enough data

Not enough reported data to compute this.

Receivable days vs history+9 daysWithin range

Debtor days are above the median of the previous three fiscal years by 9 days (42 vs 33). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress—Not enough data

Not enough reported data to compute this.

Payable days+39 days / 2 yrsNear threshold

Days payable changed by +39 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, DIIs trimmed 1.8 pts; FIIs trimmed 1.1 pts.
The number of shareholders rose from 68,598 to 80,005 (+17%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters60.4%60.4%0.0 pts

FIIs6.8%5.7%-1.1 pts

DIIs21.7%19.9%-1.8 pts

Public and others11.1%14.1%+3.0 pts

Number of shareholders

80,005shareholders+17% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−6.5%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like SANOFI INDIA LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −24% to +18% vs the market, against −6% for all non-financial companies in the same months.
The gap against the base rate (−0.8%, 80% range −7.0% to +2.9%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median

−6.5%

All companies' median

−5.7%

Beat the market

40% vs 44%

50 past situations · 50 companies · 33 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
CASTROLIND Energy Minerals	May 2023	13x	61%	+3%	−17%	+21%
PGHL Health Technology	Jan 2024	36x	45%	+25%	−6%	−3%
GLAXO Health Technology	Oct 2022	13x	37%	−8%	−27%	−6%
ACCELYA Technology Services	Nov 2020	14x	51%	−9%	−21%	−13%
OFSS Technology Services	Jan 2023	12x	36%	−14%	−20%	+61%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
INGERRAND Producer Manufacturing	Feb 2021	28x	28%	+16%	−13%	+49%
SWARAJENG Producer Manufacturing	Apr 2021	24x	39%	+50%	−13%	−17%
3MINDIA Producer Manufacturing	Jun 2025	53x	41%	−23%	−29%	+15%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and debt/equity. Not used (unavailable for this company): interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SANOFI INDIA LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

JYOTHY LABSJYOTHYLAB

Consumer Non-Durables

70%similar

market capdebt/equity

EMAMIEMAMILTD

Consumer Non-Durables

67%similar

operating marginvolatility

INDIAMART INTERMESHINDIAMART

Retail Trade

67%similar

P/Evolatility

DHANUKA AGRITECHDHANUKA

Process Industries

63%similar

operating marginrevenue

INDIAN RAIL CAT AND TOUR IRCTCIRCTC

Consumer Services

59%similar

volatilityROCE

PROCTER AND GAMBLE HEALTHPGHL

Health Technology

71%similar

ROCEdebt/equity

CAPLIN POINT LABORATORIESCAPLIPOINT

Health Technology

48%similar

revenuedebt/equity

AJANTA PHARMAAJANTPHARM

Health Technology

46%similar

volatilityROCE

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

28 events since Mar '19

2026
OctPriceFell 69% from the Jun 2024 peak to the Oct 2026 low.
OctPriceVolume reached 13.6x its 50-day median on 2026-10-30; price +0.5% that day.
JulPriceVolume reached 7.5x its 50-day median on 2026-07-29; price +1.7% that day.
MarValuationP/E fell below the 10th percentile of its own history to date (17.5x).
FebPriceVolume reached 12.7x its 50-day median on 2026-02-26; price -2.9% that day.
2025
DecPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
OctPriceVolume reached 11.0x its 50-day median on 2025-10-29; price -0.4% that day.
JulPriceVolume reached 5.3x its 50-day median on 2025-07-07; price -1.3% that day.

Show 20 earlier events

2025
MarResultsRevenue (TTM) reached a new high of ₹2,014 cr.
FebPriceVolume reached 36.7x its 50-day median on 2025-02-28; price +0.5% that day.
2024
DecPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
AugPriceVolume reached 6.8x its 50-day median on 2024-08-29; price +0.4% that day.
JunPriceVolume reached 13.8x its 50-day median on 2024-06-10; price +4.1% that day.
MarPriceVolume reached 5.1x its 50-day median on 2024-03-27; price +3.3% that day.
FebPriceRegained the 2021-08 peak, 12 months after the low.
2023
OctPriceVolume reached 7.8x its 50-day median on 2023-10-11; price +0.8% that day.
AugPriceVolume reached 10.3x its 50-day median on 2023-08-07; price +5.1% that day.
MayPriceVolume reached 33.0x its 50-day median on 2023-05-11; price +8.9% that day.
FebPriceFell 42% from the Aug 2021 peak to the Feb 2023 low.
FebPriceVolume reached 23.2x its 50-day median on 2023-02-27; price +5.4% that day.
2022
NovPriceVolume reached 9.4x its 50-day median on 2022-11-25; price +3.5% that day.
JulPriceVolume reached 21.7x its 50-day median on 2022-07-14; price +1.2% that day.
2021
JulPriceVolume reached 22.5x its 50-day median on 2021-07-28; price +1.6% that day.
2020
AprPriceVolume reached 8.0x its 50-day median on 2020-04-15; price +4.3% that day.
FebPriceVolume reached 18.0x its 50-day median on 2020-02-26; price +1.4% that day.
2019
OctPriceVolume reached 14.4x its 50-day median on 2019-10-11; price +3.1% that day.
JulPriceVolume reached 13.4x its 50-day median on 2019-07-30; price -1.7% that day.
MarPriceVolume reached 21.1x its 50-day median on 2019-03-07; price -2.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history33 months · 2024-03 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	18.5x	₹2014 cr	48.1%	49.0%	0.0x
2026-10	17.4x	₹2014 cr	48.0%	49.0%	0.0x
2026-09	16.6x	₹2014 cr	48.0%	49.0%	0.0x
2026-08	17.0x	₹2014 cr	48.0%	49.0%	0.0x
2026-07	18.1x	₹2014 cr	48.0%	49.0%	0.0x
2026-06	18.5x	₹2014 cr	48.0%	49.0%	0.0x
2026-05	16.9x	₹2014 cr	48.0%	49.0%	0.0x
2026-04	18.5x	₹2014 cr	48.0%	49.0%	0.0x
2026-03	17.5x	₹2014 cr	48.0%	49.0%	0.0x
2026-02	21.6x	₹2014 cr	48.0%	49.0%	0.0x
2026-01	21.9x	₹2014 cr	48.0%	49.0%	0.0x
2025-12	22.3x	₹2014 cr	48.0%	49.0%	0.0x
2025-11	23.9x	₹2014 cr	48.0%	49.0%	0.0x
2025-10	26.0x	₹2014 cr	48.0%	49.0%	0.0x
2025-09	25.3x	₹2014 cr	48.0%	49.0%	0.0x
2025-08	28.0x	₹2014 cr	48.0%	49.0%	0.0x
2025-07	31.7x	₹2014 cr	48.0%	49.0%	0.0x
2025-06	34.7x	₹2014 cr	48.0%	49.0%	0.0x
2025-05	33.7x	₹2014 cr	48.0%	49.0%	0.0x
2025-04	32.4x	₹2014 cr	48.0%	49.0%	0.0x
2025-03	31.2x	₹2014 cr	48.0%	49.0%	0.0x
2025-02	24.5x	₹1968 cr	45.3%	—	0.0x
2025-01	27.0x	₹1968 cr	45.3%	—	0.0x
2024-12	30.0x	₹1968 cr	45.3%	—	0.0x
2024-11	27.2x	₹1935 cr	52.2%	—	0.0x
2024-10	28.9x	₹1935 cr	52.2%	—	0.0x
2024-09	30.0x	₹1935 cr	52.2%	—	0.0x
2024-08	27.9x	₹1986 cr	54.2%	—	0.0x
2024-07	27.1x	₹1986 cr	54.2%	—	0.0x
2024-06	26.6x	₹1986 cr	54.2%	—	0.0x
2024-05	28.9x	₹1996 cr	59.4%	—	0.0x
2024-04	27.9x	₹1996 cr	59.4%	—	0.0x
2024-03	27.2x	₹1996 cr	59.4%	—	0.0x

Methodology and data notes